TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

NewLink Genetics (NLNK) Upgraded From Sell to Hold
MARKETS

PhotoMedex (PHMD) Stock Gaining on Brands Sale

  • By Amanda Schiavo
  • Jun 23, 2015 10:34 AM EDT
Time Inc. to Partner With Barclays to Launch Fortune 500 Equal Weighted Index
OPINION

3 Stocks Under $10 Making Big Moves

  • By Roberto Pedone
  • Jun 16, 2015 1:49 PM EDT
Just What Jittery U.S. Markets Don't Need -- More Global Growth Worries
INVESTING

4 Stocks Under $10 Making Big Moves Higher

  • By Roberto Pedone
  • Apr 21, 2015 1:41 PM EDT
Today's Weak On High Volume Stock: Ocean Rig UDW (ORIG)
MARKETS

Weak On High Volume: Mela (MELA)

  • By Marissa Goodbody
  • Mar 12, 2015 10:01 AM EDT
Why Portola Pharmaceuticals (PTLA) Stock is Plunging Today
INVESTING

5 Stocks Under $10 Set to Soar on Big Breakouts: Charts

  • By Roberto Pedone
  • Mar 12, 2015 9:31 AM EDT
Dow Jones (DJIA) Today: Goldman Sachs Group (GS) Higher
MARKETS

3 Stocks Pushing The Health Services Industry Lower

  • By TheStreet Wire
  • Oct 22, 2014 4:32 PM EDT
'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab
INVESTING

SEC Slaps Biotech Hedge Fund for Short-Selling Violations

  • By Adam Feuerstein
  • Sep 16, 2014 1:04 PM EDT
EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel
STOCKS

EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel

  • By Adam Feuerstein
  • Jun 12, 2014 8:00 AM EDT
'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab
STOCKS

Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts

  • By Adam Feuerstein
  • Nov 22, 2013 6:00 AM EST
4 Stocks Under $10 Making Big Moves
INVESTING

5 Stocks Under $10 Set to Soar

  • By Roberto Pedone
  • Apr 25, 2013 1:44 PM EDT
4 Under-$10 Biotech Stocks in Breakout Territory
INVESTING

4 Biotech Stocks Spiking on Unusual Volume

  • By Roberto Pedone
  • Jan 8, 2013 2:13 PM EST
MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales
STOCKS

Biotech Stock Mailbag: Sarepta, Acadia, Vical and a Hep C Preview

  • By Adam Feuerstein
  • Nov 9, 2012 6:30 AM EST
Dating Sites: Best, Worst & Weirdest
STOCKS

MELA Sciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript

  • By Seeking Alpha
  • Aug 8, 2012 5:19 PM EDT
Gilead: Hepatitis C Sales Guidance for 2015 Focus of Tuesday's Earnings Report
STOCKS

Biotech Stock Mailbag: Mela, Osiris, Talon

  • By Adam Feuerstein
  • Aug 3, 2012 6:00 AM EDT
Inflating Market Bubble Not Quite Ready to Pop
MARKETS

4 Stocks Under $5 Making Big Up Moves

  • By Roberto Pedone
  • Jul 10, 2012 2:06 PM EDT
Stocks Begin 2014 With Inflating Bubbles
MARKETS

4 Stocks Under $10 Soaring in a Weak Tape

  • By Roberto Pedone
  • Jun 1, 2012 1:41 PM EDT
Dating Sites: Best, Worst & Weirdest
PERSONAL FINANCE

Best-Performing Stocks Under $5 in 2011

  • By Robert Holmes
  • Sep 28, 2011 1:58 PM EDT
5 Hated Earnings Stocks You Should Love
INVESTING

7 Stocks Rising on Unusual Volume

  • By Stockpickr Staff
  • Sep 27, 2011 2:01 PM EDT
Uncertainty Remaining in Boston Scientific
STOCKS

Mela Device Approval a Win With Conditions

  • By Adam Feuerstein
  • Sep 26, 2011 10:54 AM EDT
Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Biotech Stock Mailbag: Vivus

  • By Adam Feuerstein
  • Sep 16, 2011 5:48 AM EDT
CTI Biopharma Posts Positive Myelofibrosis Study Results
STOCKS

Analyst, Bullish on Mela, Misquotes FDA

  • By Adam Feuerstein
  • Sep 12, 2011 11:41 AM EDT
FDA Tells Delcath No Approval Without New Clinical Trial
STOCKS

Biotech Stock Mailbag: Mela Sciences

  • By Adam Feuerstein
  • Sep 9, 2011 6:08 AM EDT
FDA Tells Delcath No Approval Without New Clinical Trial
STOCKS

Mela Sciences to FDA: Review MelaFind -- Now!

  • By Adam Feuerstein
  • May 9, 2011 10:36 AM EDT
Galapagos Receives a Rousing Welcome on Its First Day of Trading
STOCKS

Biotech Stock Mailbag: To Dividend, or Not

  • By Adam Feuerstein
  • Mar 4, 2011 7:10 AM EST
Dating Sites: Best, Worst & Weirdest
INVESTING

Lucas Energy, Hercules Offshore: Small-Cap Winners

  • By Shanthi Bharatwaj
  • Mar 2, 2011 1:04 PM EST
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.